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Allogeneic hematopoietic stem cell (HSC) transplantation
(HSCT) involves the infusion of HSCs and immune cells of
donor origin. The goals of transplantation are to achieve
sustained donor-derived engraftment without graft-versus-
host disease (GVHD), effective immune reconstitution, and
protection against malignant relapse. Immune factors of
donor and recipient origin play a crucial role in engraftment,
GVHD, graft-versus-leukemia effects, and immune recovery.
This review therefore focuses on an update in the histo-
compatibility criteria considered for the optimal selection of
unrelated donors. Furthermore, the increasingly stringent
human leukocyte antigen (HLA)-match criteria for volunteer
donors in combinationwith broadening allograft indications,
increasing diversity of patient ancestry, and shrinking family
size indicate that an increasing number of patients are
without either HLA-identical related or suitable volunteer
donors. We therefore also update the current status of
alternative donor transplantation using either haploidentical
or cord blood (CB) grafts.HISTOCOMPATIBILITY CRITERIA FOR SELECTION OF
DONORS IN ALLOGENEIC HSCT
HLA Factors Affecting Engraftment
The most important factors that increase the risk for
primary graft failure are (1) the patient’s HLA homozygosity
at a mismatched locus [1], (2) HLA mismatches in the
host-versus-graft direction [1,2], (3) the presence of donor-
speciﬁc anti-HLA antibodies (DSA) in the recipient pre-
transplant [3,4], and (4) major ABO mismatch. When
immunized by blood products, patients who are homozy-
gous at a given HLA locus tend to produce allo-antibodies
that react with a large number of alleles of the same locus.
Because the HLA alleles share T cell and B cell epitopes with
alleles of the same and other loci, individuals who are
heterozygous at a given locus may have higher chances of
sharing HLA epitopes with individuals carrying different HLA
alleles. The lower responsiveness to HLA antigens observed
in heterozygous individuals may result from tolerance to the
shared epitopes, whereas the HLAmismatch for homozygous
patients may bemore immunogenic as theywould recognize
more epitopes as foreign.
Antigen-level HLA mismatches (allele differences that
deﬁne serologic epitopes) appear to play a more signiﬁcant
role than allelic mismatches (differences that can only be
recognized by alloreactive T lymphocytes) [5]. In general,Financial disclosure: See Acknowledgment on page S95.
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the antigen recognition site (ARS). Because the antigen-level
mismatches can be distinguished by allo-antisera, it can be
speculated that the correlation between such mismatches in
the host-versus-graft vector and increased graft failure risk
may result from graft destruction by the recipient’s immune
system, including preformed recipient alloantibodies that
react with the donors’ mismatched HLA antigens.
In the past, the assessment of DSA was performed by
crossmatch tests [2] or screening the patient’s serum against
a lymphocyte panel from different subjects. These tests
present technical and logistical challenges [4] and have been
replaced by solid-phase immunoassays that use puriﬁed
molecules corresponding to single HLA and allow the accu-
rate identiﬁcation of HLA-antibody speciﬁcities. Studies
indicate that the detection of DSA in the patient’s pretrans-
plant serum increases graft failure risk [3,4]. Moreover, it
appears that the strength or titers of the anti-HLA antibodies
as well as the type of HLA target molecules have distinctive
impact on outcome. The molecules encoded by the HLA-A,
-B, and -DRB1 loci are expressed at high density on the
HSC cell surface and other cell types. In contrast, the mole-
cules encoded by HLA-DRB3, -DRB4, -DRB5, -DQ, and -DP loci
appear to be expressed at lower density. HLA-C molecules
appear to be expressed at lower density as well; however, the
role of HLA-C antibodies has not been extensively evaluated.
The HLA loci can therefore be classiﬁed as high expression
(HEL) and low expression (LEL) loci. It appears that anti-HLA
antibodies directed against products of the HEL have a more
deleterious impact in HSCT outcome and are associated with
a higher rejection risk compared with anti-HLA antibodies
reactive with LEL molecules. Moreover, DSA reactive with
molecules of LEL or HEL are associated with worse outcomes
compared with HLA-matched transplants or in patients
whose sera do not react with the HLA-mismatched antigens
of their donor.HLA Mismatches Associated with GVHD and Transplant-
Related Mortality
A single mismatch in either HLA-A, -B, -C, or -DRB1 loci is
associated with a worse outcome compared with transplants
in which the patient and donor are matched [5-8]. Trans-
plants involving multiple HLA mismatches have even worse
outcomes. Using a matching score based on the number of
matched alleles of these loci (totaling a maximum of 8), it is
agreed that a 6/8 or higher match grade in these loci is the
minimum acceptable donorerecipient match grade [5,6].
Many centers do not accept less than a 7/8 (or 9/10 if HLA-DQ
is included) match grade. The single mismatch at each of the
LEL loci does not appear to have a signiﬁcant impact inTransplantation.
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mismatches at the LEL loci (three or more) may be associated
with worse outcomes compared with transplants with one
or no mismatches at these loci in transplants performed
across a single HEL mismatch (7/8) (M. Fernandez Vina,
manuscript in preparation, 2012).
Studies have shown that either allele- or antigen-level
mismatches in HLA-A, -B, or -DRB1 loci or antigen-level
mismatches in HLA-C have a similarly deleterious impact in
transplant outcomes when compared with 8/8 HLA-matched
transplants [5-8]. In contrast, studies including principally
European patients and donors have shown that C-allelee
level mismatches do not have an adverse impact in trans-
plant outcome [5,6]. In these studies, the mismatch including
C*03:03/C*03:04 was by far the most common allele-level
mismatch in HLA-C. Therefore, the lack of signiﬁcance of
HLA-C allele mismatch may be attributed only to this pair of
alleles [9]; other less-common HLA-C mismatches may
represent a similar risk for GVHD and transplant-related
mortality (TRM) as observed for mismatches at other HLA
loci or HLA-C antigen mismatches.
In almost all studies published, the HLA mismatches have
been assigned on the basis of structural differences in the
distal membrane regions deﬁned by the alpha-1 and alpha-2
domains of HLA class I and the alpha-1 and beta-1 domains
of HLA class II molecules [5-8] that deﬁne the ARS. The amino
acid variations in these domains are likely to deﬁne
distinctive peptide-binding abilities and interactions with
the T cell receptor. Although the reasons for the large
repertoire of alloreactive T lymphocytes have not been
elucidated, it is thought that the mismatches in alleles that
present differences in their peptide-binding repertoire/T cell
receptor interactions result in immunogenic mismatches and
strong alloreactivity. Alleles differing in residues located at
the ARS are likely to bind different peptide repertoires of self-
peptides. Therefore, alleles with differences in peptide/TCR
contact sites most likely will have different three-molecular
complex moieties. These moieties will therefore be recog-
nized as foreign. The T cell alloreactivity through the recog-
nition of HLA mismatches appears to play a major role in the
causation of acute GVHD and TRM. However, some pairs of
alleles differ only in residues that do not contact with the
HLA bound peptides; these alleles may have virtually iden-
tical peptide-binding repertoires. The mismatch between
subjects carrying alleles differing outside the peptide-
binding contact sites may be less or nonimmunogenic.
Transplants in which the donor and the recipient present
only a mismatch in the above-mentioned pair of HLA-C*03
alleles or in pairs of alleles differing only in residues
located outside the ARS may have a similar outcome as fully
matched transplants.
HLA Mismatches Associated with Reduced Relapse
Acute GVHD can be associated with a decreased risk for
relapse. Some studies have shown that in 8/8 or 10/10 HLA-
matched transplants, a single or a double mismatch in HLA-
DP is associated with an increased risk of acute GVHD and
a decreased risk for relapse. Because the mismatch in DPB1
does not result in an increased risk for mortality, the detri-
mental effects of acute GVHD appear to be balanced by the
beneﬁt of decreased relapse [6]. Some suggest that the
mismatches in HLA-DP are associated with an increased risk
of mild acute GVHD in 8/8 or 10/10 matched transplants. In
7/8 transplant groups, the addition of a DP mismatch does
not seem to be associated with a decreased risk for relapse[6] (M. Fernandez Vina, manuscript in preparation, 2012).
Overall, studies indicate that in allogeneic HSCT, HLA
matching presents an overall beneﬁcial effect. The deliberate
choice of donors with mismatches in patients at high relapse
risk is controversial and is not currently recommended. In
nonmalignant diseases [8], mismatches in HLA should be
avoided because GVHD will not be beneﬁcial. Furthermore,
graft failure risk can be higher in some nonmalignant
diseases and the impact of host-versus-graft mismatches
may be higher in these patients.
Summary of HLA Considerations in Unrelated Donor
Selection
Histocompatibility factors play signiﬁcant roles in allo-
geneic HSCT outcome and must be taken into consideration
in optimal donor selection. HLA matching to the highest
possible level provides the highest beneﬁt for most patients.
If no HLA-identical donors can be identiﬁed, the following
should be considered: (1) the presence of DSA; (2) prioritize
donors with a minimal number of mismatches; (3) for
donors with 1 mismatch in HEL loci (7/8 transplants),
prioritize those with a minimal number of mismatches at the
LEL loci (DRB3/4/5, DQ, DP); and (4) if the risk of rejection is
minimized (eg, excluding donors against which the patient
has DSA), then donors with a host-versus-graft vector
mismatch and no graft-versus-host vector mismatch
(patients homozygous in one HLA locus) can be given
priority. In the absence of extensive literature, the prioriti-
zation criteria for selection are based on observations [10]
and analyses of structural differences (eg, ARS versus non-
ARS differences) between the mismatched alleles.
HAPLOIDENTICAL TRANSPLANTATION IN 2013
Forpatientsunable toﬁnda fullymatcheddonor, theuseof
a haploidentical related donor who shares 1 haplotype on
chromosome 6, as well as additional antigens in some cases
on the nonshared haplotype, is an option that increases
allograft access. An advantage of haploidentical donors is that
one is available for a highpercentage of patients becausemost
individuals have a parent, a child, or a haploidentical sibling.
Indeed, many individuals have several potential donors, and
in these cases selection criteria include the degree of HLA
match, the presence of anti-HLA antibodies, the age of the
donor, and with some transplant indications and regimens
the potential for natural killer (NK) alloreactivity. In addition,
haploidentical donors are usually rapidly available and highly
committed to supplying additional cellular therapy products
if requested. There is also a greater likelihood for identity
between minor histocompatibility antigens than when
unrelated donors are used. The use of haploidentical donors,
however, has been historically limited by the increased risk of
alloreactivity, resulting in a higher incidence of rejection,
GVHD, and prolonged immunodeﬁciency with an increased
risk of infection [2,11]. These risks increasewith the degree of
mismatch so that transplants from donors mismatched in
a single antigen produce results equivalent to those achieved
with matched sibling donors, whereas greater degrees of
mismatch produce inferior outcomes. Several strategies have
therefore been explored tomanipulate HSC products used for
transplantation or to eliminate the cells that mediate
alloreactivity.
Haploidentical Transplantation with T Cell Depletion
One strategy is to administer a product that has been
engineered to extensively deplete alloreactive T cells. This
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stimulating factoremobilized, large-volume apheresis and
CD34þ cell selection. Patients who receive such products
have a low risk of grades II to IV GVHD [12]. In a phase II study
the 2-year probability of event-free survival for patients with
acute leukemia in remission was 48% for acute myelogenous
leukemia and 46% for acute lymphoblastic leukemia [12].
However, delayed immune reconstitution after CD34-
selected transplants results in a signiﬁcant risk of infection
[11]. An alternate strategy is to deplete T cell populations,
allowing transfer of NK cells and other CD3- cells present in
the infused product [13]. In several recently published
pediatric series, selective T cell depletion resulted in 2-year
event-free survival of 26% to 88% depending on the
regimen and the risk of the underlying hematologic malig-
nancy [13]. In a recent multicenter study in adults using
a CD3/19-depleted peripheral blood stem cell product, the
incidence of grades II to IV acute and chronic GVHD was 46%
and 18%, respectively, and survival was 41% at 1 year and 28%
at 2 years [14].
Haploidentical Transplantation with T Replete Regimens
An approach developed by investigators at Johns Hopkins
administers unmanipulatedmarrowand relies on high-dose,
post-transplantation cyclophosphamide (50 mg/kg on post-
transplant days 3 and 4) to eliminate alloreactive cells
in vivo. This strategy is based on murine studies showing
that high-dose cyclophosphamide given early post-
transplant can deplete alloantigen activated alloreactive
T cells [15]. In a review of 212 patients with advanced
hematologic malignancies treated on trials with this
strategy, the cumulative incidence of grades II to IV acute
GVHD and chronic GVHD were 28% and 14%, respectively,
and the 2-year progression-free survival was 34% [15]. One
major advantage of this approach is that it is technically
much simpler than T cell depletion and so has been
successfully implemented in many other centers. A recently
completed Bone Marrow Transplant Clinical Trials Network
multicenter study evaluated post-transplantation cyclo-
phosphamide in patients receiving haploidentical marrow
after a conditioning regimen of cyclophosphamide, ﬂudar-
abine, and 200 cGy of total body irradiation. The 1-year
probabilities of overall and progression-free survival in 50
patients after haploidentical marrow transplantation were
62% and 48%, respectively, conﬁrming the feasibility and
exportability of this approach [16].
Several groups in China have administered unmanipu-
lated marrow or mobilized peripheral blood and relied on
anti-thymocyte globulin (ATG) to eliminate alloreactive
cells [17]. Investigators at Peking University reported
outcomes in a large number of patients who received
granulocyte colony-stimulating factoreprimed marrow or
granulocyte colony-stimulating factoremobilized periph-
eral blood from haploidentical donors. In 820 patients with
hematologic malignancies, the 3-year leukemia-free
survival rates were 67.9% in standard risk and 48.8% in
high-risk patients with a 2-year risk of 52.9% for chronic
GVHD (23.4% extensive) [17].
There has been no formal comparison between different
approaches, although one single-center study comparing
consecutive patients with the same conditioning regimen
after a change from CD34 selection to post-transplantation
cyclophosphamide suggested better early results with
T cellereplete grafts due to a lower risk of infectious
complications [18]. It is difﬁcult to compare regimens,however, because they targeted different populations and
diseases. For example, many of the T cell depletion studies
targeted pediatric patients, and the regimens developed in
China have not yet been widely evaluated in other
countries.
Immunotherapy Strategies after Haploidentical
Transplantation
Because relapse remains a major cause of failure after all
the above approaches and infections are a signiﬁcant cause of
morbidity and mortality after T celledepleted grafts, there is
much interest in approaches to augment antitumor and
antiviral immunity after haploidentical transplant using NK
alloreactivity or T cell therapies. NK cell alloreactivity has
been reported to reduce the risk of relapse after T celle
depleted haploidentical transplantation [19]. Killer cell
immunoglobulin-like receptor ligands on NK cells recognize
HLA class I alleles, and mismatching in the donor-versus-
recipient direction is associated with decreased risk of
relapse and improved survival in patients receiving CD34þ
cell selected haploidentical transplantation for acute
myelogenous leukemia and also in some series of pediatric
acute lymphoblastic leukemia [19]. These beneﬁts have not
been observed, however, with T-replete haploidentical
transplants.
Because of the immune deﬁciency observed after
T celledepleted transplants, there has been interest in add-
ing back T cells to reconstitute immunity. As even small
numbers of T cells may potentially induce severe GVHD,
several groups evaluated the use of T cells genetically
modiﬁed to express a suicide gene so they can be ablated
if GVHD occurs [20,21]. This approach has progressed to
late-phase testing in Europe and has resulted in not only
broad T cell recovery with transduced cells but improved
reconstitution with nontransduced recent thymic emigrants
[22]. An alternative approach is to infuse regulatory T cells in
conjunction with unmanipulated T cells, and a recent
study showed that adoptive transfer of regulatory T cells
followed by conventional T cells in the absence of any
post-transplantation immunosuppression could enhance
immunity to pathogens without inducing GVHD [23].
Antigen-speciﬁc T cells have also been infused to treat viral
infections without inducing alloreactivity after hap-
loidentical transplantation [24], and several groups are
exploring strategies to expand thymic precursors [11].
CB TRANSPLANTATION IN 2013
CB represents a critically important alternative HSC
source for mixed and minority patients because it enables
administration of a T replete graft but with reduced strin-
gency of required HLA match. Analysis of the ancestry of
patients (n ¼ 657) (updated from Barker et al. [25]) who
underwent adult volunteer donor and unrelated CB trans-
plantations (CBTs) from October 2005 to June 2012 at
Memorial-Sloan Kettering Cancer Center (MSKCC) showed
that 4-6/6 HLA-A,-B antigen, -DRB1 allele matched CB units
can extend transplant access to southern, eastern, and mixed
European as well as non-European patients. In this analysis,
whereas the 465 unrelated volunteer donor transplant
recipients had predominantly (n ¼ 351, 75%) European
backgrounds, over 50% of the 156 CBT recipients were non-
European in origin. Patients without an adult volunteer or
CB graft (n ¼ 36) during this period represented only 5% of
the group in need of an alternative donor transplant. These
data provide deﬁnitive evidence that CB extends transplant
Table 1
Comparison of Single-Unit CBT with Adult Donor HSCT
Series No. Patients/
Graft
Median
Age
Disease-Free
Survival
Comment
Eapen et al., Lancet 2007 [40]: Children <16 yr
with acute leukemia
503 CBT: 35 matched CB
201 1-Ag MM
44 high dose
157 low dose
267 2-Ag MM
208 BM:
116 matched
166 MM
Unknown
60% @ 5 yr
45% @ 5 yr
36% @ 5 yr
33% @ 5 yr
38% @ 5 yr
37% @ 5 yr
Supports CB as immediate alternative to URD BM
transplantation with a potential advantage of
6/6 matched CB grafts
Zhang et al., BBMT 2012 [41]: Children with
ALL in second complete remission
94 matched RD
81 matched URD
88 MM URD
86 CB
8 yr
URDs:
7 yr
6 yr
50% @ 3 yr
44% @ 3 yr
44% @ 3 yr
43% @ 3 yr
Supports CB as alternative if no matched RD or
matched BM
Takahashi et al.,
Blood 2007 [42]: Adults with heme
malignancy
100 CBT
71 matched RD:
55 BM, 16 PBSC
38 yr
40 yr
70% @ 3 yr
60% @ 3 yr
Supports CB as alternative to matched sibling
donor transplant
Atsuta et al.,
Blood 2009 [43]: Adults with acute
leukemia
287 CBT
173 AML
114 ALL
533 matched URD
311 AML
222 ALL
38 yr
34 yr
38 yr
32 yr
42% @ 2 yr
46% @ 2 yr
54% @ 2 yr
44% @ 2 yr
CB was inferior in AML (due to higher TRM) but
similar in ALL
Eapen et al.,
Lancet Oncol. 2010 [44]: Adults with acute
leukemia
165 CB
888 PBSC
632 matched
265 1-Ag MM
472 BM
332 matched
140 1-Ag MM
28 yr
39 yr
33 yr
44% @ 2 yr*
50% @ 2 yr*
39% @ 2 yr*
52% @ 2 yr*
41% @ 2 yr*
Disease status was only factor associated with DFS
and was independent of HSC source
Ag indicates antigen; MM, mismatched; BM, bone marrow; DFS, disease-free survival; DCBT, double-unit CBT; RD, related donor; PBSC, peripheral blood stem
cells; URD, unrelated donor; AML, acute myeloid leukemia; CR2, second complete remission; ALL, acute lymphoid leukemia.
* If transplanted in remission.
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guarantee transplant access regardless of race.
In addition to its use in extending transplantation access
to minorities, CB is also useful for those in need of urgent
transplantation and, as a cryopreserved HSC source, enables
easy rescheduling of transplant admission. This can be of
special importance in patients with complex pretransplant
workups. However, the advantages of CB can only be fully
realized if transplantation with acceptable TRM can be ach-
ieved. Recognition of the poor engraftment and high TRM
rates after myeloablative single-unit CBT has appropriately
triggered extensive investigation into a variety of approaches
to improve CBT outcomes.Preparative Regimens and Immune Suppression
From the standpoint of regimen intensity, the recognition
of the marked toxicity associated with high-dose myeloa-
blative preparative regimens has led to investigation of
nonmyeloablative conditioning, most commonly with the
cyclophosphamide 50 mg/kg, ﬂudarabine 200 mg/m2, and
total body irradiation 200 cGy pioneered by the University of
Minnesota. This has been associated with improved tolera-
bility and the consequent ability to offer CBT up to approxi-
mately 70 years of age in suitable candidates. However, the
recognition of a signiﬁcant incidence of relapse after non-
myeloablative CBT of 31% at 1 year in the series reported by
Brunstein et al. [16] prompted investigation of reduced-
intensity approaches that are functionally myeloablative
and represent regimens of intermediate intensity. Examples
include the cyclophosphamide 50 mg/kg, ﬂudarabine
150 mg/m2, thiotepa 10 mg/kg, and total body irradiation
400 cGy conditioning developed by MSKCC (J. Barker,manuscript submitted, 2012); the melphalan 140 mg/m2,
ﬂudarabine 160 mg/m2, and thiotepa 10 mg/kg regimen of
the MD Anderson Cancer Center [26]; and melphalan
100 mg/m2 and ﬂudarabine 150 mg/m2 from the Boston
group [27]. Regimens of intermediate intensity are promising
additions to the CBT ﬁeld and require further investigation
as potential alternatives to both high-dose and non-
myeloablative conditioning.
The immunosuppression used for CBT has also varied.
Calcineurin-inhibitor/mycophenolate mofetilebased regi-
mens without ATG have been associated with promising
immune recovery [28] but with signiﬁcant rates of graft-
versus-host disease. For example, in 115 double-unit CBT
recipients (median age, 37 years) undergoing transplantation
for hematologic malignancies, day 180 rates of grades II to IV
and III to IV acute GVHDwere 53% and 23%, respectively, with
a 23% chronic GVHD incidence at 2 years (J. Barker, manu-
script submitted, 2012). An alternative approach is more
intensive in vivo T cell depletion with ATG with consequent
reduced rates of 14% grades II to IV and 3% grades III to IV
acute GVHD, for example, reported by Chen et al. [27].
However, ATG-based regimens have been associated with
increased incidences of opportunistic infections, including
Epstein-Barr virus and lymphoproliferative disease, and the
potential for an increased relapse risk. At this time the
optimal GVHD prophylaxis is not established and requires
further investigation.Variations in the CB Graft
Manipulations in CB graft have been even more varied.
The simplest approach has been the use of double units to
augment graft dose with series of double-unit CBT,
Table 2
Comparison of Double-Unit CBT with Adult Donor HSCT
Series No. Patients/Graft Median Age Survival
(PFS or DFS)
Comments
Brunstein et al., Blood 2010 [31]:
>10 yr, myeloablation for leukemia
128 DCB
204 MRD
152 M-URD
52 MM-URD
25 yr
40 yr
31 yr
31 yr
51% @ 5 yr
33% @ 5 yr
48% @ 5 yr
38% @ 5 yr
DCB is suitable alternative if
no matched donor.
Ponce et al., BBMT 2011 [39]:
Children and adults for heme malignancy
75 DCB
108 RD
184 URD
37 yr
47 yr
48 yr
55% @ 2 yr
66% @ 2 yr
55% @ 2 yr
Comparable PFS regardless of
HSC source.
Brunstein et al., Blood 2011 [16]:
Adult RIC CB and haplo for leukemia and lymphoma
50 DCB
50 haplo BM
58 yr
48 yr
46% @ 1 yr
48% @ 1 yr
Multicenter replication of
single-center results. Requires
larger series and longer follow-up
to establish utility of both approaches.
Brunstein et al., Blood 2012 [45]: Adult RIC in acute
leukemia
120 DCB (CyFluTBI200)
40 DCB (Other)
313 8/8 PBSC
111 7/8 PBSC
55 yr
48 yr
59 yr
58 yr
31% @ 2 yr
15% @ 2 yr
35% @ 2 yr
29% @ 2 yr
No difference between
CyFluTBI200 DCBT and 7/8 and
8/8 PBSC transplants.
Chen et al., BBMT 2012 [27]:
Adult RIC in heme malignancy
64 DCB
221 URD
53 yr
58 yr
30% @ 3 yr
40% @ 3 yr
DCBT suitable alternative if no
matched URD.
PFS indicates progression-free survival; DFS, disease-free survival; DCB, double-unit cord blood; MRD, matched related donor; M, matched; MM, mismatched;
URD, unrelated donor; RIC, reduced-intensity conditioning; haplo, haploidentical; BM, bone marrow; PBSC, peripheral blood stem cell; Cy, cyclophosphamide;
Flu, ﬂudarabine; TBI, total body irradiation.
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compared with historical single-unit controls. A recent
analysis of MSKCC double-unit CBT recipients (n ¼ 92)
undergoing transplantation for acute leukemia in morpho-
logic remission or aplasia and myelodysplasia/myeloprolif-
erative disease with 5% blasts at workup has shown 2-year
disease-free survival of 72% in children (median age, 7 years;
range, .9 to 15) and 65% in adults (median age, 47 years;
range, 16 to 69) (J. Barker, unpublished data, 2012). The
relatively high survival rates are contributed to by relatively
low rates of relapse: 17% in children and 7% in adults at
2 years in this analysis. Relapse rates may be reduced after
double-unit CBT as compared with that observed after
single-unit CBT as reported in multiple series [29-31],
including a prospective randomized study from Kindwall-
Keller et al. [32].
However, CB grafts have become even more complex
than just the delivery of 2 units. In a large part due to the
cost of double-unit grafts, multiple investigators have
sought to optimize single-unit CBT with intrabone injection,
single-unit transplantation with factors to enhance homing,
single units with a portion of the graft ex vivo expanded,
and single units combined with T celledepleted hap-
loidentical cells. Originally pioneered by the Fernandez
group in Madrid, this approach has been further developed
to incorporate reduced-intensity conditioning with prom-
ising progression-free survival of 42% in a high-risk patient
population transplanted after reduced-intensity condi-
tioning [33]. Moreover, in an effort to further improve
double-unit grafts, CBT has been investigated with one-unit
unmanipulated and one ex vivo expanded, single, or
double-unit grafts with additional third-party, CB-derived
cells to act as a source of myeloid progenitors, engineered
CB-derived cytotoxic T cells, or ex vivo generated NK or
regulatory T cells (all reviewed in [34]), or double units
combined with T celledepleted haploidentical HSC
currently under investigation at MSKCC.
Which approaches will come to replace unmanipulated
single-unit and double-unit CBT and how the spiraling costs
of CB grafts and additional cellular therapy can be contained
remain to be established. However, in the interim guidelines
for unit selection have undergone signiﬁcant evolution[35,36]. Analysis of the combined effect of total nucleated cell
dose and HLA-A, -B antigen, -DRB1 allele match in single-
unit CBT has revealed the lowest TRM is associated with
units with 0 mismatch regardless of dose, emphasizing the
importance of match [37]. Furthermore, Eapen et al. recently
demonstrated increased TRM associated with HLA-C
mismatch, suggesting CB match criteria should be reas-
sessed [38]. However, given the median donorerecipient
match grade of infused CB units is 6/10 HLA alleles in MSKCC
CBT recipients [39], how to trade off high-resolution match
against dose and howmuch mismatch is too much remain to
be determined. To add even further complexity, the recog-
nition of the importance of unit quality adds a further
dimension to considerations of unit selection.Comparison of Single- and Double-Unit CBT with Adult
Donor Transplantation
Themultitude of variables in CBTcanmake comparison of
CBT outcomes to unrelated and haploidentical transplants
challenging. However, it is striking that multiple studies have
emerged suggesting comparable disease-free survival can be
achieved after CBT as that observed after adult donor allo-
grafts. The results of select studies comparing single-unit and
double-unit CBT to adult donor transplantation are
summarized in Tables 1 and 2, respectively. Importantly, the
results of such studies should prompt centers to abandon
futile unrelated donor searches and pursue CB or hap-
loidentical transplants (according to local expertise) for
those in need of prompt allografting, given the data suggest
such transplants are a suitable alternative for patients with
high-risk hematologic malignancies.ACKNOWLEDGMENT
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